Segments - Home Diagnostics Market by Test Type (Pregnancy Test, Glucose Monitoring Test, HIV Test, Cholesterol Detection Test, Ovulation Predictor Test, Infection Test, Drug Abuse Test, and Others.), Form (Strips, Cassettes, Midstream, and Dip Cards), Distribution Channel (Retail Pharmacies, Hypermarket & Supermarkets, and Online Pharmacies), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031.
The global home diagnostics market size was USD 6.16 Billion in 2022 and is likely to reach USD 9.31 Billion by 2031, expanding at a CAGR of 4.7 % during 2023–2031. The market growth is attributed to the increasing incidence of various chronic diseases such as diabetes, blood pressure home pregnancy test kits, and others.
Home diagnostic kits such as pregnancy test strips are utilized in the home pregnancy test which measures the presence of a human chorionic gonadotropin (hCG) in the urine to reveal the result. Thus, the growing adoption of home pregnancy tests is expected to boost the demand for home diagnostics.
Home diagnostics is a collection of diagnostic kits that individuals use at home without requiring medical expertise. These test kits are deployed at patients' homes to provide information on personal health traits, monitor present health conditions, and diagnose a previously undiagnosed medical condition. The primary purpose of home diagnostics is to detect disease, its spread in the body, and its outlook.
Increasing incidence of diabetes is projected to fuel the market as diabetic patients require regular blood sugar monitoring to maintain their sugar levels. A home diagnostics device such as a glucometer is utilized to monitor the blood sugar levels of diabetic patients at home by providing real-time information about the glucose level in the blood. Thus, increasing cases of diabetes are expected to boost the demand for home diagnostics. For instance,
According to the International Diabetes Federation, in 2021 537 million adults aged between 20 and 79 years are living with diabetes, and expected to reach 643 million by 2030.
The COVID-19 pandemic propelled the demand for home diagnostics. COVID-19 infection directly affects the respiratory system and the blood sugar level of diabetic patients, resulting in dysregulation of glycemic control, which leads to an increase in fasting blood glucose and HbA1c. This propelled the need for home diagnostics as these kits are required to maintain the correct blood sugar level by continuous monitoring of the blood sugar levels of diabetic patients. Moreover, the introduction of a home kit for COVID-19 testing boosted the demand for home diagnostics as with this kit patients perform the self-swab at home. For instance,
On April 21, 2020, LabCorp a leading global life sciences company introduced the Pixel COVID-19 test home collection kit. This kit has received the Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).
The integration of artificial intelligence in home diagnostics plays a crucial role in the early detection of disease by finding minute patterns and abnormalities by analyzing vast patient records that indicate a disease's presence. AI-powered home diagnostic devices use machine learning algorithms to learn from various datasets and they utilize predictive analytics for early diagnosis of diseases. Moreover, key companies in the market are introducing home diagnostic devices powered with artificial intelligence (AI) and smart IoT, which is expected to boost the demand for AI-powered home diagnostic devices. For instance,
On January 6, 2022, BlueSemi an emerging Indian health tech start-up launched EYVA at Consumer Electronics Show (CES) 2022. EYVA has the potential to measure 6 key body vitals such as SPo2, ECG, Heart rate, Blood glucose, Blood pressure, and Temperature within 60 seconds. EYVA is backed by innovative technology and features such as AI algorithms, sensor fusion, and smart IoT.
Growing geriatric population is expected to boost the demand for home diagnostics. Older people need a home diagnosis to live a quality life as it allows seniors to stay near their loved ones and friends which reduces loneliness and mental issues like anxiety and depression. Moreover, taking elderly people to a hospital is challenging and risky due to the involvement of more time, which propels the need for home diagnosis. Thus, the rising geriatric population is expected to drive the market. For instance,
As per the report published by the World Health Organization on October 1, 2022, 1 in 6 people in the world will be aged 60 years or over by 2030 and the number is expected to reach 2.1 billion by 2050.
Increasing incidence of chronic diseases is projected to drive the market. Chronic diseases are long-lasting conditions that cause poor mental health outcomes which require home diagnosis monitoring to control the disease by maintaining a balance between mind and body.
For instance,
According to the report published by the World Health Organization on September 16, 2023, every year 41 million people are killed globally due to non-communicable diseases (NCDs) also known as chronic diseases, which is equivalent to 74% of all deaths globally.
The misinterpretation of test results in home diagnosis is expected to restrict market growth. Some diagnosis tests are complex to interpret and lead to the wrong medications or therapies, which causes long-term injuries or fatalities, thus hampering the market demand for home diagnosis. Moreover, the complexity involved in choosing proper test kits for home diagnosis is anticipated to impede market growth.
Increasing adoption of self-testing and the rising incidence of online diagnosis creates an immense opportunity in the market as home diagnosis devices and instruments are utilized in self-testing and online diagnosis. Moreover, rising investment in research and development activities by major companies to introduce new home diagnosis devices creates a lucrative opportunity in the market. For instance,
On January 18, 2023, Cipla an Indian multinational pharmaceutical company introduced a point-of-care testing device Cippoint for infectious diseases, non-communicable diseases, and other health conditions. It offers a wide range of testing parameters such as fertility, thyroid function, diabetes, infectious diseases, coagulation markers, cardiac markers, inflammation, and metabolic markers.
The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Home Diagnostics Market- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Test Type (Pregnancy Test, Glucose Monitoring Test, HIV Test, Cholesterol Detection Test, Ovulation Predictor Test, Infection Test, Drug Abuse Test, and Others.), Form (Strips, Cassettes, Midstream, and Dip Cards), and Distribution Channel (Retail Pharmacies, Hypermarket & Supermarkets, and Online Pharmacies) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Abbott; SelfDiagnostics Deutschland GmbH; F. Hoffmann-La Roche AG; Cue Health Inc.; ARKRAY, Inc; Trinity Biotech; Mylab Discovery Solutions Pvt. Ltd.; Bionime Corporation; Quidel Corporation; BD; ACON Laboratories, Inc.; Abingdon Health; Cipla Inc.; SA Scientific Ltd.; BTNX Inc.; Thermo Fisher Scientific Inc.; and BlueSemi. |
Based on test type, the home diagnostic market is segregated into pregnancy tests, glucose monitoring tests, HIV tests, cholesterol detection tests, ovulation predictor tests, infection tests, drug abuse tests, and others. The pregnancy test segment held a large market share in 2022, due to the rising demand for fast and self-testing kits by working women. The pregnancy test is required in home diagnosis to check the signs of pregnancy by checking the specific hormone (hCG) through blood or urine samples. Moreover, the introduction of new and affordable at-home pregnancy test kits by major market players is boosting the demand for pregnancy tests and home diagnoses. For instance,
On June 9, 2022, Mylab an Indian diagnostic company introduced an at-home pregnancy test kit PregaScreen. PregaScreen allows women to detect their pregnancy status at home.
The glucose monitoring test segment is projected to grow at a high CAGR during the projected period, owing to the increasing prevalence of diabetes around the world. The glucose monitoring test is required in home diagnosis to monitor the blood sugar levels of a diabetic and the effect of diabetes medications. This test provides information about blood sugar levels such as high or low blood sugar levels and is used to maintain the blood sugar level of diabetic patients. Thus, the rising prevalence of diabetes is expected to propel the demand for glucose monitoring tests and significantly for home diagnosis. For instance,
According to a report published by the National Institute of Health, the global diabetes prevalence is expected to rise by 10.9% and cross 700 million diabetic patients by 2045 compared to 463 million people in 2019.
In terms of form, the global market is categorized into strips, cassettes, midstream, and dip cards. The cassette segment accounted for a major market share in 2022, due to the wide adoption of pregnancy test kits and urine tests. Cassettes are utilized in pregnancy kits to detect a hormone in urine that the body produces during pregnancy. The cassette is used for rapid tests for diagnostic kits and is used in single-way and multi-way as per patients' requirements, which encourages patients to adopt cassettes for rapid tests.
The strip segment is anticipated to grow at a considerable pace during the assessment period, owing to detect the presence of a disease in the body such as diabetes. Strips are commonly used in diabetes diagnosis at home for taking readings of blood sugar levels, which is projected to boost the demand for strips and significantly for home diagnosis.
Based on distribution channels the home diagnostics market is divided into retail pharmacies, hypermarkets & supermarkets, and online pharmacies. The retail pharmacies dominated the market in 2022, due to the wide presence of retail pharmacy stores across the globe and their ability to provide quality assurance of the products. Retail pharmacies offer a large variety of assured quality home diagnosis devices such as glucometers, pregnancy test kits, COVID test kits, and others with easy availability which encourages patient and their relatives to purchase home diagnosis kits from retail pharmacies. Thus, boosting the demand for retail pharmacies and home diagnostics.
The online pharmacies segment is expected to witness considerable growth in the coming years, owing to the increasing consumer preference for online medication. Online pharmacies enhance customer convenience by delivering medicines to patients' locations on time, which propels patients to purchase their medicine and home diagnosis kits from online pharmacies. Moreover, online pharmacies provide exciting discounts and deals to patients that reduce the cost of medicines and motivates patients to adopt online pharmacy for buying medication.
Based on region, the home diagnostic market is segregated into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a large market share in 2022, due to the presence of key market players such as Abbot, Quidel Corporation, BD, and ACON Laboratories, Inc. Moreover, the rising penetration of diabetes in the region is expected to boost the demand for home diagnostics as home diagnostics devices are required for monitoring and maintaining the blood sugar level of diabetic patients at home. For instance,
According to the American Diabetes Association, 37.3 million Americans had diabetes in 2019 and the number is expected to increase by 1.4 million every year.
Asia Pacific is anticipated to witness quick growth during the forecast period, owing to the rising prevalence of various diseases coupled with the increasing population. Moreover, rising awareness among people about self-testing and self-diabetes management is driving the market growth in the region. Additionally, the growing geriatric population is projected to boost the demand for home diagnosis as aging leads to chronic illness in the geriatric population which requires regular and timely health check-ups to ensure there is no disease progression. For instance,
As per the report published by the United States Census Bureau on June 21, 2022, the number of Asian people aged 65 and over is 414 million and it is expected to triple over the next 4 decades.
The home diagnostics market has been segmented on the basis of
Key players competing in the global market are Abbott; SelfDiagnostics Deutschland GmbH; F. Hoffmann-La Roche AG; Cue Health Inc.; ARKRAY, Inc.; Trinity Biotech; Mylab Discovery Solutions Pvt. Ltd.; Bionime Corporation; Quidel Corporation; BD; ACON Laboratories, Inc.; Abingdon Health; Cipla Inc.; SA Scientific Ltd; BTNX Inc.; Thermo Fisher Scientific Inc.; and BlueSemi.
These companies adopted development strategies including collaboration, product launches, mergers, acquisitions, partnerships, and production expansion to expand their consumer base worldwide. For instance,
On March 13, 2023, Cue Health a healthcare technology company introduced the new suite of consumer-friendly, at-home diagnostic test kits. These diagnostic kits are easy to use and provide individuals with reliable testing from the comfort of their own homes, making it easier for people to take control of their health.
On February 7, 2023, Abingdon Health a leading manufacturer of rapid test kits announced the distribution agreement with Salignostics for the launch of SalistickTM the first saliva-based pregnancy test kit. The pregnancy test kit is saliva-based that offers women an innovative and improved user experience with high accuracy for early pregnancy detection.